Q3 2024 EPS Estimates for Black Diamond Therapeutics, Inc. Decreased by Wedbush (NASDAQ:BDTX)

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) – Investment analysts at Wedbush dropped their Q3 2024 earnings per share (EPS) estimates for shares of Black Diamond Therapeutics in a research report issued to clients and investors on Monday, October 7th. Wedbush analyst R. Driscoll now expects that the company will earn ($0.40) per share for the quarter, down from their prior estimate of ($0.29). Wedbush currently has a “Outperform” rating and a $16.00 price objective on the stock. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($1.40) per share. Wedbush also issued estimates for Black Diamond Therapeutics’ Q4 2024 earnings at ($0.40) EPS, FY2024 earnings at ($1.54) EPS, Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.99) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.86) EPS and FY2028 earnings at $1.35 EPS.

Black Diamond Therapeutics (NASDAQ:BDTX) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03.

Several other analysts also recently commented on the company. Raymond James started coverage on Black Diamond Therapeutics in a research note on Wednesday, July 31st. They set an “outperform” rating and a $20.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Black Diamond Therapeutics in a report on Wednesday. Finally, Piper Sandler raised their price target on Black Diamond Therapeutics from $12.00 to $15.00 and gave the company an “overweight” rating in a report on Monday, September 23rd.

Black Diamond Therapeutics Trading Down 3.1 %

BDTX stock opened at $3.44 on Thursday. The stock’s 50 day simple moving average is $5.13 and its 200 day simple moving average is $5.29. Black Diamond Therapeutics has a 12-month low of $1.62 and a 12-month high of $7.66. The stock has a market capitalization of $193.51 million, a PE ratio of -2.07 and a beta of 2.47.

Institutional Investors Weigh In On Black Diamond Therapeutics

Several large investors have recently made changes to their positions in BDTX. Susquehanna Fundamental Investments LLC purchased a new position in Black Diamond Therapeutics in the first quarter worth about $82,000. Acadian Asset Management LLC raised its stake in Black Diamond Therapeutics by 13.8% in the first quarter. Acadian Asset Management LLC now owns 170,510 shares of the company’s stock worth $864,000 after buying an additional 20,616 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Black Diamond Therapeutics during the second quarter worth $108,000. Bank of New York Mellon Corp acquired a new position in shares of Black Diamond Therapeutics during the second quarter worth $508,000. Finally, Rhumbline Advisers increased its position in shares of Black Diamond Therapeutics by 10,334.3% during the second quarter. Rhumbline Advisers now owns 46,850 shares of the company’s stock worth $218,000 after purchasing an additional 46,401 shares in the last quarter. 95.47% of the stock is owned by institutional investors.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.